Cellino Biotech

Executive Summary

Cellino Biotech is a private biotechnology company pioneering an autonomous, AI-driven biomanufacturing platform for personalized regenerative medicine. Founded in 2017 and headquartered in Cambridge, MA, the company aims to address the scalability challenges in producing patient-specific cell therapies. Its proprietary Nebula™ platform integrates AI, laser optics, and closed-loop bioprocessing to enable the automated, reproducible manufacturing of 'living medicines'—personalized cell, tissue, and organ replacements derived from a patient's own cells. This technology has the potential to transform the treatment of degenerative diseases by making cell therapies more accessible and affordable. Cellino operates at the intersection of AI and cell therapy, a rapidly growing field. While still in a pre-clinical or early development stage, the company has attracted significant attention for its innovative approach. Its platform could reduce the cost and failure rates associated with manual cell manufacturing, positioning it as a key enabler of the cell therapy revolution. Near-term milestones likely include securing Series C financing to advance platform development and preclinical studies, as well as potential collaborations with pharmaceutical partners to validate its technology for specific indications. The company's differentiation lies in its fully automated, closed-loop system, which could offer a significant competitive advantage in the emerging personalized cell therapy market.

Upcoming Catalysts (preview)

• Q4 2026Series C Funding Announcement60% success
• H1 2027Strategic Partnership with a Major Pharma Company50% success
• Q2 2027First IND Filing for Lead Indication40% success